Toxicology, ISSN 0300-483X, 2011, Volume 288, Issue 1, pp. 1 - 7
Abstract Hydroquinone (HQ) is an environmental contaminant which causes immune toxicity. In this study, the effects of exposure to low doses of HQ on...
Emergency | Adhesion molecules | Mice | Environmental contaminant | Oxidative burst | DNA fragmentation | PARA-BENZOQUINONE | DNA-ADDUCTS | CELLS | APOPTOSIS | GRANULOCYTIC DIFFERENTIATION | FACTOR-KAPPA-B | ADHESION | INHIBITION | BENZENE METABOLITES | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Bronchoalveolar Lavage Fluid | Hydroquinones - administration & dosage | Lung - pathology | Lipopolysaccharides - toxicity | Neutrophils - drug effects | Male | Cell Adhesion Molecules - metabolism | Respiratory Burst - drug effects | Dose-Response Relationship, Drug | Cell Movement - drug effects | Hydroquinones - toxicity | Animals | Flow Cytometry | Lung - drug effects | Environmental Pollutants - administration & dosage | DNA Fragmentation - drug effects | Environmental Pollutants - toxicity | Neutrophils - metabolism | Cell Adhesion Molecules - drug effects | Disease Models, Animal | Inflammation - physiopathology | Biological apparatus and supplies | Inflammation | DNA | Enzyme-linked immunosorbent assay | Endothelium | Integrins | Index Medicus
Emergency | Adhesion molecules | Mice | Environmental contaminant | Oxidative burst | DNA fragmentation | PARA-BENZOQUINONE | DNA-ADDUCTS | CELLS | APOPTOSIS | GRANULOCYTIC DIFFERENTIATION | FACTOR-KAPPA-B | ADHESION | INHIBITION | BENZENE METABOLITES | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Bronchoalveolar Lavage Fluid | Hydroquinones - administration & dosage | Lung - pathology | Lipopolysaccharides - toxicity | Neutrophils - drug effects | Male | Cell Adhesion Molecules - metabolism | Respiratory Burst - drug effects | Dose-Response Relationship, Drug | Cell Movement - drug effects | Hydroquinones - toxicity | Animals | Flow Cytometry | Lung - drug effects | Environmental Pollutants - administration & dosage | DNA Fragmentation - drug effects | Environmental Pollutants - toxicity | Neutrophils - metabolism | Cell Adhesion Molecules - drug effects | Disease Models, Animal | Inflammation - physiopathology | Biological apparatus and supplies | Inflammation | DNA | Enzyme-linked immunosorbent assay | Endothelium | Integrins | Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 06/2018, Volume 391, Issue 10136, pp. 2236 - 2271
A key component of achieving universal health coverage is ensuring that all populations have access to quality health care. Examining where gains have occurred...
TRANSITION | MEDICINE, GENERAL & INTERNAL | STATES | INEQUALITIES | CAUSE-SPECIFIC MORTALITY | COVERAGE | INDICATOR | AMENABLE MORTALITY | TRENDS | LIFE EXPECTANCY | NATIONS | Global Burden of Disease | Communicable Diseases - epidemiology | Health Services Accessibility | Humans | Noncommunicable Diseases - epidemiology | Wounds and Injuries - epidemiology | Quality of Health Care | Health care | Populations | Disease | Personal health | Health services | Mortality | Health care policy | Health risks | Principal components analysis | Exposure | Risk analysis | Sustainable development | Risk factors | Diseases | Charities | Demographics | Maternal & child health | Correlation analysis | Collaboration | Quality | Trends | Public health | Service areas | Cancer | Morbiditat | Medical care | Assistència mèdica | Morbidity | Hälsovetenskaper | Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi | Medical and Health Sciences | Medicin och hälsovetenskap | Public Health, Global Health, Social Medicine and Epidemiology | Health Sciences | Nutrition and Disease | HNE Nutrition and Disease | Chair Nutrition and Disease | Voeding en Ziekte | VLAG | HNE Voeding en Ziekte
TRANSITION | MEDICINE, GENERAL & INTERNAL | STATES | INEQUALITIES | CAUSE-SPECIFIC MORTALITY | COVERAGE | INDICATOR | AMENABLE MORTALITY | TRENDS | LIFE EXPECTANCY | NATIONS | Global Burden of Disease | Communicable Diseases - epidemiology | Health Services Accessibility | Humans | Noncommunicable Diseases - epidemiology | Wounds and Injuries - epidemiology | Quality of Health Care | Health care | Populations | Disease | Personal health | Health services | Mortality | Health care policy | Health risks | Principal components analysis | Exposure | Risk analysis | Sustainable development | Risk factors | Diseases | Charities | Demographics | Maternal & child health | Correlation analysis | Collaboration | Quality | Trends | Public health | Service areas | Cancer | Morbiditat | Medical care | Assistència mèdica | Morbidity | Hälsovetenskaper | Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi | Medical and Health Sciences | Medicin och hälsovetenskap | Public Health, Global Health, Social Medicine and Epidemiology | Health Sciences | Nutrition and Disease | HNE Nutrition and Disease | Chair Nutrition and Disease | Voeding en Ziekte | VLAG | HNE Voeding en Ziekte
Journal Article
Rodriguesia, ISSN 0370-6583, 10/2015, Volume 66, Issue 4, pp. 1085 - 1113
Abstract An updated inventory of Brazilian seed plants is presented and offers important insights into the country's biodiversity. This work started in 2010,...
Biomes | Life-forms | Endemism | Angiosperms | Gymnosperms | life-forms | endemism | biomes
Biomes | Life-forms | Endemism | Angiosperms | Gymnosperms | life-forms | endemism | biomes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The...
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article